

# BIOHK2023

香港國際生物科技論壇暨展覽

DISCOVER THE LIMITLESS  
POTENTIAL OF HONG KONG'S  
BIOTECH ECOSYSTEM

# CONFERENCE

---

## DAY FOUR

Saturday September 16

# 招商永隆銀行 服務香港 90 年



「一點通」



招商永隆銀行網站

查詢熱線：230 95555 網址：www.cmbwinglungbank.com 關注官方微信：cmbwinglungbank

服務及優惠受有關條款及細則約束

招商永隆銀行有限公司



招商永隆銀行  
CMB WING LUNG BANK

因您而變 成就無限

08:30	EVENT REGISTRATION 活动登记			
	BIOHK AUDITORIUM			
09:00 - 09:30	<p><b>中国生物产业的发展与机遇</b> KEYNOTE SESSION: <b>PROF. FU GAO 高福</b> (ACADEMICIAN, CHINESE ACADEMY OF SCIENCES) 主讲嘉宾: 高福院士 (中国科学院)</p>			
09:30 - 10:00	<p><b>NOVEL BIOTECHNOLOGY FOR EARLY CANCER DETECTION</b> KEYNOTE SESSION: <b>PROF. TONY MOK 莫树锦</b> (CHINESE UNIVERSITY OF HONG KONG) 主讲嘉宾: 莫树锦教授 (香港中文大学)</p>			
10:00 - 10:30	<p><b>FROM SARS TO COVID, WHAT HAVE WE LEARNT?</b> KEYNOTE SESSION: <b>PROF. FAN NGAI HUNG 孔繁毅</b> (THE UNIVERSITY OF HONG KONG) 主讲嘉宾: 孔繁毅教授 (香港大学)</p>			
10:30 - 10:40	BREAK			
	BIOHK AUDITORIUM	INNOVATION GALLERIA	TECHNOLOGY HALL	LOCI SQUARE
10:40 - 11:30	<p><b>SPONSOR: CSBT &amp; IMCAS</b> 赞助商: 中国生物工程学会 &amp; 中国科学院微生物研究所</p> <p><b>BIOSAFETY 生物安全</b> 10:40-11:40</p> <p>Rational Vaccine Design: From Zika to COVID-19 Dr. Liansan Dai (IMCAS) 戴连攀博士 (中国科学院微生物研究所)</p> <p>Computational Redesign of Functional Enzymes Dr. Brian Wu (IMCAS) 吴边博士 (中国科学院微生物研究所)</p> <p>Target Tumor Microenvironment to Rejuvenate T-cell Immune Response Dr. Longchao Liu (IMCAS) 刘龙超博士 (中国科学院微生物研究所)</p>	<p><b>PROBIOTICS 益生菌</b> 10:40-11:40</p> <p>Moderator: Mr. Edmond Lau (HK Business Angel Network) 主持人: Edmond Lau 先生 (香港天使投资网络)</p> <p>Dr. Matey Yordanov (The Matrix Cube) Matey Yordanov 博士 (The Matrix Cube)</p> <p>Dr. Mikhail Bychov (Vim Vitae) Mikhail Bychov 博士 (Vim Vitae)</p>	<p><b>GET PUBLISHED IN NATURE 在自然杂志发表论文</b> 10:40-11:30</p> <p>Ms. Mimmi Mononen (Nature Journal) Mimmi Mononen 女士 (自然杂志)</p>	<p><b>POC TECHNOLOGIES POC 技术</b> 10:40-12:40</p> <p><b>PRODUCT SHOWCASE 产品展示</b></p> <p>eNano Health 依纳康科技 Innovation in Cancer Therapy with Nuclear Medicine 核医学的肿瘤创新治疗</p> <p>Airdoc 鹰瞳科技 The world's leading AI-based retinal imaging examination system 世界领先的人工智能视网膜成像检查系统</p>
11:30 - 13:00	<p><b>RETHINKING DRUG DISCOVERY AND REPURPOSING 老药新用</b> 11:40-13:00</p> <p>Dr. Tien Lee (Aardark Therapeutics) Tien Lee 博士 (Aardark Therapeutics)</p> <p>Prof. Wai Lung Ng (Chinese University of Hong Kong) 吴维龙教授 (香港中文大学)</p> <p>Fast Forwarding Research: Exploiting Approved Drugs Dr. Yu Wai Chen (Hong Kong Polytechnic University) 陈友权博士 (香港理工大学)</p> <p>AI-driven de novo protein design for therapeutics (人工智能和生成式算法驱动的蛋白质设计) Dr. Fan Liu (neoX Biotech) 刘帆博士 (北京星九原生物科技)</p>	<p><b>STEM EDUCATION AND BIOTECHNOLOGY STEM 教育和生物科技</b> 11:40-12:10</p> <p>Prof. Fei Sun (HKUST) 孙飞教授 (香港科技大学)</p> <p>Prof. Jiguang Wang (HKUST) 王吉光教授 (香港科技大学)</p> <p>Dr. Zhaoshi Bao (Capital Medical University) 葆璋实博士 (首都医科大学北京天坛医院)</p> <p>张卓瀚先生 (卓瑞国际集团)</p>	<p><b>VOICES OF GBA SCHOLARS 大湾区学者之声</b> 11:30-13:00</p> <p>Ubiquitin-mediated Proteolysis in Cancer Development and Therapy Prof. Hai Rao (Southern University of Science and Technology) 饶海教授 (南方科技大学)</p> <p>Gut Microbes Modulate Systemic Inflammation and Behaviour Disorders in Neurologic Disease Prof. Wenjing Zhao (Sun Yat-sen University [Shenzhen]) 赵文婧教授 (中山大学 [深圳])</p> <p>Bistable Insulin Response as the Stability Anchor Governing Body Mass Dynamics: Weight Stability, Weight Gain, and Beyond Dr. Guanyu Wang (The Chinese University of Hong Kong [Shenzhen]) 王冠宇博士 (香港中文大学 [深圳])</p> <p>Po19-mediated mitotic DNA damage repair suppresses nuclear envelope reassembly defect under replication stress Dr. Lin Deng (Shenzhen Bay Laboratory) 邓麟博士 (深圳湾实验室)</p> <p>Volumetric compression by heterogeneous scaffold embedding promotes cerebral organoid maturation and growth Dr. Shaohua Ma (Tsinghua Shenzhen International Graduate School) 马少华博士 (清华大学深圳国际研究生院)</p>	
13:00 - 14:00	LUNCH BREAK			
14:00 - 16:00	<p><b>SPONSOR: CAIR-HKISI-CAS</b> 赞助: 中科院香港创新研究院人工智能与机器人创新中心</p> <p><b>AI &amp; ROBOTICS IN HEALTHCARE 医疗保健中的人工智能与机器人</b> 14:00-16:00</p> <p>Chair 主席: Dr. Hongbin Liu (CAIR-HKISI, Chinese Academy of Sciences) 刘宏斌博士 (中国科学院香港创新研究院人工智能与机器人创新中心)</p> <p>Robotic Neurosurgery in the Era of AI Keynote: Dr. Danny Chan (Chinese University of Hong Kong) 主讲嘉宾: 陈达明博士 (香港中文大学医学院)</p> <p>Surgical Motion Generation and Perception Towards Intelligent Minimally Invasive Robotic Procedures 智能微创机器人手术运动生成和感知 Dr. Hongliang Ren (Chinese University of Hong Kong) 任洪亮博士 (香港中文大学)</p> <p>Digital Twin for Brain Surgery Training, Planning and Navigation. 用于脑外科手术培训, 规划导航的数字孪生系统 Dr. Zhongkai Zhang (CAIR-HKISI, Chinese Academy of Sciences) 张忠凯博士 (中国科学院香港创新研究院人工智能与机器人创新中心)</p> <p>Drugcompass: AI-based Exploration of Drug Interactions 基于人工智能的药物交互作用探索 Dr. Qingpeng Zhang (The University of Hong Kong) 张清鹏博士 (香港大学同心基金)</p> <p>Continuum Robots and Artificial Intelligence for use in Healthcare and General Applications 连续机器人和人工智能用于医疗保健和一般应用 Dr. Kar Hang Henry Chu (The Hong Kong Polytechnic University) 朱嘉行博士 (香港理工大学机械工程系)</p>	<p><b>THE LOOP 河套论坛</b></p>	<p><b>SPECIAL EVENT COMING SOON 特别活动即将推出</b></p>	<p><b>SPECIAL EVENT: COMMUNITY EVENT 特别活动: 基层医疗健康</b></p>

ONEZONE PARTNERING

# KEYNOTE ADDRESS

Saturday, September 16 | 09:00 AM - 10:40 AM (GMT+8)

09:00 - 09:05	<b>WELCOME REMARKS</b> <b>CHRIS PANG, HONG KONG BIOTECHNOLOGY ORGANIZATION</b>
09:05 - 09:35	<b>KEYNOTE SESSION: PROF. GEORGE GAO FU, ACADEMICIAN, CHINESE ACADEMY OF SCIENCE</b>
09:35 - 10:05	<b>KEYNOTE SESSION: PROF. TONY MOK, CHAIRMAN, DEPARTMENT OF CLINICAL ONCOLOGY, THE CHINESE UNIVERSITY OF HONG KONG</b> <b>Novel Biotechnology for Early Cancer Detection</b>
10:05 - 10:35	<b>KEYNOTE SESSION: PROF. IVAN HUNG, CHAIR OF INFECTIOUS DISEASES, THE UNIVERSITY OF HONG KONG</b> <b>From SARS to COVID, what have we learnt?</b>
10:35 - 10:40	<b>Coffee Break</b>

Invest**HK**

BIOHK2023 SILVER SPONSOR

**Hong Kong**  
**Where**  
**Business**  
**Goes to**  
**Grow**





# **Fu Gao 高福**

**Member of Chinese Academy of Sciences, China**

---

Professor George F. Gao obtained his PhD (DPhil) degree from Oxford University, UK and did his postdoc work in both Oxford University and Harvard University (with a brief stay in Calgary University). His research interests include enveloped viruses and molecular immunology. His group research is mainly focusing on the enveloped virus entry and release, esp. influenza virus interspecies transmission (host jump), structure-based drug-design and structural immunology. He is also interested in virus ecology, esp. the relationship between influenza virus and migratory birds or live poultry markets and the bat-derived virus ecology and molecular biology. He has published more than 500 refereed papers (Including papers in Cell, Nature, Science, The Lancet, New England Journal of Medicine, Proceedings of the National Academy of Sciences USA etc.), 10 books or book chapters and holds more than 25 UK, US and Chinese patents. His research has recently expanded on public health policy and global health strategy. He led the China CDC team in 2014 (From September to November, when the disease went to its sky-high level) to work in Sierra Leone for fighting against Ebola and his heroic role there has made a great deal for the field work. He works hard now for establishing an Africa-based center for pathogens and tropical diseases.

Gao is a member (academician) of Chinese Academy of Sciences (elected in 2013), a fellow of The Third World Academy of Sciences (TWAS, also known as The World Academy of Sciences) (elected in 2014), a fellow of American Academy of Microbiology (AAM, elected in 2015); an associate (foreign) member of EMBO (European Molecular Biology Organization) (elected in 2016), a fellow of AAAS (American Association for the Advancement of Science) (elected in 2016), a fellow of RSE (Royal Society of Edinburgh) (elected in 2017), a fellow of AAS (African Academy of Sciences) (elected in 2017), a member (academician) of International Eurasian Academy of Sciences.



# CRRT智慧解决方案 SMARTCRRT 信息化软件

## 武汉聚智惠仁信息技术有限公司

武汉聚智惠仁信息技术有限公司成立于2019年。是一家专注赋能医疗行业智能、智慧解决方案的专业新锐信息化公司。公司由国内顶级医学专家团队，行业资深市场团队和极富持续创新创业经验的管理团队共同组建。

### 使命

我们将通过新一代信息技术的智慧支撑与仁心妙术的专业学术体系深度融合，聚时代之智，惠天下以仁！

### 愿景

我们立志成为智慧医疗信息化在CRRT(CCBP)治疗领域行业标准创建者和领路人！

力争在未来为1000家重点医院，每年约100万重症患者提供优质服务！



### 智慧诊疗

智能辅助治疗，智能助手，预警平台；移动办公，帮助医生时刻守护患者生命。



### 智慧护理

全面掌握患者信息，AI数据采集，减轻工作负担，规范工作流程，改进工作质量。



### 智慧管理

基于优秀实践，帮助科室妥善解决质控、设备效能、绩效等管理问题。



### 智慧科研

完整数据链采集，全设备接入，形成CRRT专科病种数据库，提供数据即席



本次盛会免费注册





# **Tony Mok 莫樹錦**

**Chairman, Department of Clinical Oncology,  
The Chinese University of Hong Kong**

---

Professor Tony S.K. Mok was trained at the University of Alberta, Canada and he subsequently completed a fellowship in medical oncology at the Princess Margaret Hospital in Toronto. After working as a community oncologist in Toronto, Canada for seven years, he returned to Hong Kong in 1996 to pursue an academic career.

Professor Mok is the Li Shu Fan Medical Foundation endowed Professor and Chairman of Department of Clinical Oncology at The Chinese University of Hong Kong. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He was the Principal Investigator and first author on the landmark IRESSA® Pan-Asia Study (IPASS), which was the first study that confirmed the application of precision medicine for advanced lung cancer. He has also led and co-led multiple international phase III studies including the FASTACT 2, PROFILE 1014, IMPRESS, ARCHER 1050, ALEX, AURA 3 and KEYNOTE 042. These projects address various aspects on management of advanced lung cancer, and basically have defined the current practice. He dedicates his work on precision medicine for lung cancer by also engaging in clinical research on oncogene driven lung cancer and immunotherapy. His work has been adopted by multiple international guidelines including NCCN, AMP/IASLC/CAP, ASCO and ESMO. He also contributes to the development of clinical research infra-structure in China and Asia. He cofounded the Lung Cancer Research Group, Chinese Thoracic Oncology Research Group and Asia Thoracic Oncology Research Group.

Professor Mok has contributed to over 308 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet, Nature Medicine and Journal of Clinical Oncology, and published multiple editorials and textbooks. He served as an Associate Editor for thoracic oncology for the Journal of Clinical Oncology and other international journals. He is the Past President, Past Treasurer of the International Association for the Study of Lung Cancer (IASLC) and Past Board of Director for ASCO. He is a member of the Board of Directors for ACTG-Sanomics Group, AstraZeneca, Aurora Tele-Oncology, HutchMed (China) and St. Stephen's College & Preparatory School. He is active in international education activity and has made significant contributions to AACR, ASCO, CSCO and ESMO. His work was recognized by numerous awards including Bonnie Addario Award in 2015, Fellowship of the American Society of Clinical Oncology (FASCO) in 2017, Paul 2020, Jr Scientific Award in 2017, National Science and Technology Progress Award in 2017, CSCO Annual Achievement Award in 2017, ESMO Lifetime Achievement Award in 2018, The 6th Kobayashi Foundation Award, Giant of Cancer Care 2020 and SingTao Hong Kong Leader of the Year 2020 Award. His recent article in the New England Journal of Medicine has been selected as one of the most "Notable Articles in 2017". He is one of the "Highly Cited Researchers" by Clarivate Analytics for four consecutive years from 2018 to 2022. He was awarded with the Bronze Bauhinia Star (BBS) by the Government of Hong Kong Special Administrative Region in 2022 to recognize his dedicated service in public affairs.



## 專註於AI多靶點抗衰

賽立復是專註AI多靶點抗衰的生物科技公司，由全球頂尖高校的博士團隊打造，圍繞衰老的九大機理，依托AI多靶點抗衰研究院的衰老機製研究平臺、抗衰老物質研究平臺、先進製劑研發平臺、產品評價及臨床研究平臺等四大平臺，提供衰老幹預的個性化解決方案。

CELFULL® is a biotechnology company dedicated to AI-driven multi-target anti-aging, Created by a team of top doctoral researchers from leading universities worldwide. Centered around fermentation of nine major crops, CELFULL utilizes four major platforms: the Fermentation Mechanism Research Platform of the AI Multi-Target Anti-Aging Research Institute, the Elderly Anti-Aging Biomaterial Research Platform, the Advanced Formulation Development Platform, and the Product Evaluation and Clinical Research Platform. These platforms collectively provide personalized solutions for aging-related issues in elderly individuals.

旗下品牌賽立復提供衰老及退行性疾病的個性化藥物和膳食補充劑解決方案。

The brand under its umbrella, CELFULL, offers personalized pharmaceutical and dietary supplement solutions for aging and degenerative diseases.

### 賽立復作為美國老年協會(ASA)成員一直致力於用科研助力全球健康老齡化

As a member of the American Society on Aging (ASA), CELFULL has been dedicated to using scientific research to promote global healthy aging.



#### 1 衰老機製研究平臺

Mechanism of Aging Research Platform

中科賽立復分子網絡抗衰聯合實驗室  
CAS&CELFULL Molecular Network  
Anti-aging Joint Laboratory

#### 3 先進製劑研究平臺

Advanced Agents Research Platform

賽立復線粒體醫學實驗室  
CELFULL Mitochondria Medical Laboratory

#### 2 抗衰物質研究平臺

Anti-aging Substances Research Platform

計算機輔助營養物質設計平臺  
Computer Aided Nutrients Design Platform

#### 4 產品評價與臨床研究平臺

Product Evaluation and Clinical Research Platform

賽立復-綿麗功效與安全評價聯合實驗室  
CELEULL-MANNAY Joint Laboratory Efficacy and Safety Evaluation  
中科賽立復分子網絡抗衰聯合實驗室  
CAS&CELFULL Molecular Network Anti-aging Joint Laboratory

### 四大研發平臺

AI驅動長壽產品研發  
全方位提升研發效率  
與研發應用



# 为 神经系统疾病 提供创新医疗器械解决方案

## 磁共振引导激光消融手术系统 LaserRO



- 多场景** 双光源双波长, 满足更多消融场景
- 多形态** 6种规格光纤型号选择, 配合双波长, 可实现精准适形
- 安全** 创新一体化水冷光纤导管系统, 安全可靠
- 可预见** 集术前规划, 术中监控, 术后评估于一体的全流程软件系统



## 植入式闭环自响应神经刺激系统 Epilcure

- 创新** 国内首款自主研发自反应神经刺激系统, 可实现对癫痫患者监测和刺激的闭环交互, 按需治疗
- 便捷** 可实现全颅骨植入
- 精准** 高灵敏度的局部场电位信号采集技术
- 安心** 高效能低热耗的无线充电技术



## 关于佳量

佳量医疗成立于2020年, 是一家专注于脑科学和神经外科领域的高科技平台型企业。公司已构建脑机调控、医用激光以及脑机芯片三大技术平台, 为多种神经系统疾病提供创新解决方案, 部分产品已进入临床试验阶段。

Hangzhou GenLight MedTech Medical was founded in Hangzhou in 2020, and is a high-tech platform enterprise dedicated to commercializing cutting-edge technologies in the fields of neuroscience and neurosurgery.

The company has built advanced technology platforms in three areas: Innovative brain-computer interface, advanced medical laser, and brain-computer chip. They all offer innovative medical solutions for various neurological diseases. Some of the company's products have entered the clinical trial stage.

浙江省杭州市余杭区仓前街道仓兴街1390号9幢B座

TEL: 0571-88730192

E-MAIL: support@glightmed.com





# **Fan Ngai Hung 孔繁毅**

**Ru Chien & Helen Lieh Professorship in Health Sciences  
Pedagogy, HKUMed**

Professor Ivan Fan Ngai HUNG is currently Chair of Infectious Diseases, Ru Chien and Helen Lieh Endowed Professor in Health Sciences Pedagogy, Professor of Medicine and Assistant Dean (Admissions), Chief of the Division of Infectious Diseases, Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, and Honorary Consultant in Queen Mary Hospital, Hong Kong. He is also Clinical Professor and Chief-of-Service of the Department of Infectious Diseases and Clinical Microbiology at the HKU-Shenzhen Hospital.

Professor Hung is a dual specialist in Infectious Disease and Gastroenterology & Hepatology. He obtained his medical degree from the University of Bristol Medical School, England in 1996. After working in the University of Cambridge Medical School and Charing Cross Hospital, London, he returned to Hong Kong in 1999 and joined the Department of Medicine, Queen Mary Hospital. He was awarded the Anti-SARS gold badge award by the Hospital Authority in 2003 for his role in combating SARS as frontline medical officer. He received the Sir Patrick Manson Gold Medal award for best M.D. thesis. He was awarded the Richard Yu Lectureship and medal in 2016 by the Hong Kong College of Physicians. He was awarded the prestigious Outstanding Researcher Award from the University of Hong Kong in 2019. He is the Fellow of Royal Colleges of Physicians of London and Edinburgh, and fellow of the Infectious Disease Society of America and Advisory Board Member of the Universal Scientific Education & Research Network (USERN). Professor Hung has published more than 340 international peer reviewed original articles, including research articles in the Lancet, Nature, the Lancet Infectious Diseases and the Clinical Infectious Diseases. His research interest includes influenza, SARS-CoV-2 and other respiratory virus antiviral treatment and vaccinology. He has pioneered the use of the triple combination of interferon beta-1b, lopinavir/ ritonavir and ribavirin in the treatment of hospitalized COVID-19 patients, resulting in significantly faster clinical alleviation and viral load suppression. He and his team also pioneered the application of topical imiquimod before intradermal influenza vaccination, which results in protection against heterologous non-vaccine and antigenically drifted viruses. He was also the first to prove convalescent plasma and H-IVIG reduced mortality in patients with severe influenza infection in prospective clinical trials. He is ranked as HKU Scholars in the world top 1% in 2013, 2018-2022 (H-index 63 with 20695 citations). He is the world-leading expert in the field of antiviral and vaccinology for influenza and COVID-19 infection. He is currently the Editorial Board member of the Vaccine and Diagnostics medical journals. As a clinician scientist, Professor Hung believes in innovation, team-work and clinical application of translational research in tackling threats from emerging infectious diseases.

# BIOHK AUDITORIUM | BIOHK 會堂

## Public Day: Share & Inspire

Saturday, September 16 | 10:40 AM - 16:00 PM (GMT+8)

### Biosafety (Sponsored by CSBT and IMCAS)

10:40 - 11:40

**Rational vaccine design: from Zika to COVID-19**  
Moderator: Dr. Lianpan Dai, Institute of Microbiology, Chinese Academy of Sciences\*

Panelists:  
**Computational redesign of functional enzymes**  
Dr. Bian Wu, Institute of Microbiology, Chinese Academy of Sciences

**Target tumor microenvironment to rejuvenate T-cell immune response**  
Dr. Longchao Liu, Institute of Microbiology, Chinese Academy of Sciences

### Rethinking Drugs Discovery and Repurposing

11:40 - 13:00

Dr. Tien Lee, Aardvark Therapeutics  
Prof. Wai Lung Ng, The Chinese University of Hong Kong

**Fast Forwarding Research: Exploiting Approved Drugs**  
Dr. Yu Wai Chen, Hong Kong Polytechnic University

**AI-driven de novo protein design for therapeutics (人工智能和生成式算法驱动蛋白药物设计)**  
Dr. Fan Liu, neoX Biotech

13:00 - 14:00

### Lunch Break

### AI & Robotics in Healthcare

14:00 - 14:35

**Keynote Speaker: Dr. Tat Ming Danny Chen, Chinese University of Hong Kong**  
Robotic Neurosurgery in the era of AI

14:45 - 16:00

**Surgical motion generation and perception towards intelligent minimally invasive robotic procedures**  
智能微創機器人手術運動生成和感知

Dr. Hongliang Ren The Chinese University of Hong Kong

**Drugcompass: AI-based exploration of drug interactions 基於人工智能的藥物交互作用探索**

Dr. Qingpeng Zhang, The University of Hong Kong

**Digital twin for brain surgery training, planning and navigation. 用于脑外科手术培训, 规划和导航的数字孪生系统**

Dr. Zhongkai Zhang CAIR-HKISI, Chinese Academy of Sciences\*

**Continuum Robots and Artificial Intelligence for use in Healthcare and General Applications 連續體機器人和人工智能用於醫療保健和一般應用**

Dr. Kar Hang Henry Chu The Hong Kong Polytechnic University

\*No biography or information was provided before September 01, 2023.

### Sponsored by



**中国生物工程学会**  
Chinese Society of Biotechnology



**中国科学院微生物研究所**  
INSTITUTE OF MICROBIOLOGY  
CHINESE ACADEMY OF SCIENCES



# ***Bian Wu*** 吴边

**Principal investigator**

**The Institute of Microbiology Chinese Academy of Sciences**

---

A principal investigator at the Institute of Microbiology, Chinese Academy of Sciences, Bian Wu is a recipient of the National Outstanding Young Scientists Award and serves as the chief investigator for the National Key Research and Development Program. He graduated with a degree in Pharmacy from Peking University in 2004 and earned his Ph.D. from the University of Groningen in the Netherlands in 2010. His primary research focuses on the field of microbial enzyme catalysis. In recent years, he has integrated protein computational design into enzyme engineering research. He has elucidated the detailed mechanisms of several types of microbial enzymes in catalyzing carbon-nitrogen bond formation and applied them to the precise synthesis and targeted modification of biomolecules through artificial modification. Wu Bian has published dozens of papers in prestigious academic journals such as Nature Catalysis and Nature Chemical Biology. Based on this work, he has developed a series of biosynthetic pathways for various chemicals, with several technologies like enzymatic peptide assembly,  $\beta$ -amino acid biosynthesis, and the sequential fermentation of heterocyclic drug intermediates successfully reaching industrial application. He has received multiple awards including the Hebei Province Science and Technology Progress First Prize and the Outstanding Young Enzyme Engineer Award from the Chinese Society for Microbiology. He currently serves as the director of the Enzyme Engineering Committee of the Chinese Society for Microbiology, and a council member of the China Synthetic Biology committee.



# ***Longchao Liu***

**Professor**

**Institute of Microbiology Chinese Academy of Sciences**

---

From 2011 to 2016, Prof. Liu pursued a Ph.D. in Biochemistry and Molecular Biology at the University of Chinese Academy of Sciences. Prior to that, they obtained a Bachelor of Science degree in Biotechnology from Jilin University, completing their undergraduate studies from 2007 to 2011.

Following his Ph.D., Prof. Liu embarked on post-doctoral fellow training at Dr. Yang-Xin Fu's Lab in UT Southwestern Medical Center, located in Dallas, TX, USA. They dedicated their time to research and professional growth in this role from February 2017 to November 2022.

Currently, [Name] holds the position of Principal Investigator, Professor, and Ph.D. advisor at IMCAS since January 2023. Their contributions and expertise are invaluable in advancing their field of study.

Throughout their academic journey, Prof. Liu has been recognized for their achievements. In 2018, they received the AAI Trainee Poster Award from UT Southwestern Medical Center. Additionally, during their time at the University of Chinese Academy of Sciences, they were honored as The Merit Students in 2015. Furthermore, they received The First Prize Scholarship in 2011 and were recognized as The Excellent Student Cadre in the same year at Jilin University. In 2008, they were acknowledged as Excellent Student and were awarded the National Scholarship at Jilin University.



## **Tien Lee**

**Chief Executive Officer  
Aardvark Therapeutics**

---

Dr. Lee has 20 years of experience as a biotechnology innovator and executive who has been integrally involved with the founding or advancement of several biopharmaceutical companies. Since 2017, Dr Lee has been the founder/CEO of Aardvark Therapeutics, Inc. Prior to this, Dr. Lee joined Nantkwest in 2014 and served as its Chief Strategy Officer until March, 2017. His experience includes therapeutics for immunology, cardiovascular, oncology, neurology, and infectious disease indications. Dr. Lee is also an inventor or co-inventor of multiple biomedical and biotechnology innovations, licensed or assigned to several companies for development including Nantkwest, Simcere Pharmaceutical Group, Cellics Therapeutics, and Aardvark Therapeutics. Dr. Lee earned his M.D. degree from UC San Diego and his B.A. degree from UC Berkeley in Molecular Biology where he was also a Regents and Alumni Scholar. Dr. Lee received post-graduate training in Internal Medicine through UC Los Angeles and Physical Medicine and Rehabilitation at UC Irvine.



## **Wai Lung Ng**

**Assistant Professor  
The Chinese University of Hong Kong**

---

Professor Ng's research interests are chemical biology, drug discovery, and medicinal chemistry. The Ng lab uses chemical, biological, and bioinformatics tools to develop novel small molecules for the treatment of various diseases, including cancers, infectious and neurodegenerative diseases. He has co-authored more than 20 papers in prestigious journals such as Science, Nature Chemical Biology, Molecular Cell, J. Am. Chem. Soc., Angew. Chem. Int. Ed., and ACS Central Science and also serves as a reviewer for more than 20 journals including Science Translational Medicine, Nature Chemical Biology, and Nature Communications.

Professor Ng obtained his B.Sc. degree in Chemistry (1st Class Hons.) and Ph.D. in Organic Chemistry from the Chinese University of Hong Kong (CUHK). During his graduate study, he was a Fulbright Scholar at Massachusetts Institute of Technology (MIT), under the generous funding supports from the Lee Hysan Foundation and the Fulbright Program. From 2014 – 2016, he joined the University of Oxford as a Croucher Foundation Postdoctoral Fellow. He was then recruited to Harvard Medical School / Dana-Farber Cancer Institute as a research fellow from 2016 – 2019. He was honored as a Young Global Leader (2022) by the World Economic Forum.

一期辦公研發，2024年中竣工

二期廠房

# 東莞 生物技術產業

# 中心園區

為生技企業提供優質資源和卓越服務！

東莞市生物技術產業發展有限公司

松山湖生物技術產業綜合運營服務商

公司於2012年底經東莞市政府批准在松山湖正式設立，註冊資本13億元，為松山湖高新區管委會下屬國有獨資企業，是松山湖生物技術產業綜合運營服務商，全市唯一的國有生物技術產業專業平臺。公司圍繞生物技術產業，形成產業園開發和綜合運營、產業基金投資和產業創新服務等三大主營業務，從全產業鏈著手，整合政策、資金、項目和市場等資源，與合作夥伴協同互補，以融合發展的理念，促進產業的協同發展。

公司未來將逐步建成，以生物技術產業綜合運營服務為方向，以產城開發運營為主體，以產業研發、投資與服務為核心的綜合性大型新興產業集團。

## ▶ 產業園招引企業

生物  
醫藥

醫療  
器械

智能  
穿戴


生物  
服務

生物  
信息

熱綫電話：

86-0769-22892820





## ***Yu Wai Chen*** 陳友維

**Senior Research Fellow**  
**The Hong Kong Polytechnic University**

---

YWC studied Chemistry and Biochemistry at the Imperial College London. He worked for a PhD at the MRC Centre for Protein Engineering, Cambridge, UK under the supervision of Kim Henrick and Sir Alan Fersht, and completed in 1994. He did postdoc with Gary Brayer (University of British Columbia); and subsequently John Collier (Harvard Medical School) from 1994 to 1997. Next, he moved back to Cambridge, UK and joined the late Max Perutz as a research associate until 2003; then with David Glover (Cambridge). He was a visiting professor of the Institute of Microbiology of the Chinese Academy of Sciences in 2005. From 2005 to 2015, he was a lecturer at the Randall Division of King's College London. Since 2016, he joined the Hong Kong Polytechnic University as a research staff.

YWC aspires to advance the molecular understanding of pathogens and diseases, in particular, polyglutamine expansion diseases. He is generally interested in the structural biology of proteins that have implications in human diseases: including bacterial and viral virulent factors, proteins implicated in cell cycle control, cytoskeletal components, etc.



## ***Fan Liu***

**Co-founder and Chief Technology Officer**  
**neoX**

---

Dr. Fan Liu, co-founder and CTO, is an expert in new drug discovery and development and holds a PhD degree in computational chemistry from the California Institute of Technology. His research was focused on understanding the structure of proteins from the structures to dynamics. He was a scientist at the Institute for Systems Biology and served as a principal investigator at BeiGene. Dr. Liu led and participated in a number of translational research projects of novel drugs.

Enjoy **10% OFF\***  
on your next News Release Distribution Service  
from PR Newswire

\*This offer is valid until 30 Nov 2023 for all exhibitors of BIOHK2023

PR Newswire Distribution | Empowering PR and Marketing Pros  
to **Target, Reach** and **Engage** Their Audiences



170+ Countries  
40+ Languages



850K+ Pitchable  
Contacts



440+ Media Outlets



12.1 Million Monthly  
Organic Searches

CONTACT US NOW  
TO CLAIM THE OFFER



[www.cision.asia](http://www.cision.asia)  
[www.prnewswire.com/apac](http://www.prnewswire.com/apac)



[apaccs@cision.com](mailto:apaccs@cision.com)



PR Newswire APAC





## **Danny Chan 陳達明**

**Honorary Clinical Associate Professor, Department of Surgery  
The Chinese University of Hong Kong**

Dr Danny Chan is currently a Consultant in the Division of Neurosurgery in the Prince of Wales Hospital, and Associate Director of the CUHK Otto Wong Brain Tumour Centre. Dr Chan graduated from the Chinese University of Hong Kong with MBChB in 1995, entered specialty training and subsequently obtained his FRCSEd(SN).

Dr Chan's research interests are in functional neurosurgery, deep brain stimulation and cortical mapping, with 78 relevant publications. Dr Chan is renowned for his research in the world's first intraoperative MRI-guided robot for bilateral stereotactic neurosurgery. This project explored the use of an MR-compatible teleoperation system in neurosurgery, which would represent a major step towards safer, more accurate and effective brain surgery. His research paper was conferred the Best Conference Paper Award in the IEEE International Conference on Robotics and Automation 2018.



## **Hongliang Ren**

**Associate Professor  
The Chinese university of Hong Kong**

Professor Hongliang Ren received his Ph.D. in Electronic Engineering (Specialized in Biomedical Engineering) from The Chinese University of Hong Kong (CUHK) in 2008. He has been navigating his academic journey through Chinese University of Hong Kong, UC Berkeley, Johns Hopkins University, Children's Hospital Boston, Harvard Medical School, Children's National Medical Center, United States, and National University of Singapore. He has served as an Associate Editor for IEEE Transactions on Automation Science & Engineering (T-ASE) and Medical & Biological Engineering & Computing (MBEC). He has served as an active organizer and contributor on the committees of numerous robotics conferences, including a variety of roles in the flagship IEEE Conf. on Robotics and Automation (ICRA), IEEE Conf. on Intelligent Robots and Systems (IROS), as well as other domain conferences such as MICCAI/ROBIO/BIOROB/ICIA/CVPR. He served as publicity chair for ICRA 2017, concurrently as Organizing Chair for ICRA 2017 workshop on Surgical Robots, and video chair for ICRA 2021. He has delivered numerous invited keynotes/talks at flagship conferences/workshops at ICRA/IROS/ROBIO/MICCAI/CVPR/ICIA. He is the recipient of IFMBE/IAMBE Early Career Award 2018, Interstellar Early Career Investigator Award 2018, Health Longevity Catalyst Award (2022 by NAM & RGC), NUS Engineering Young Researcher Award (2019), Interstellar Early Career Investigator Award (2018), ICBHI (Biomedical and Health Informatics) Young Investigator Award (2019), NUS Young Investigator Award (2013), EMedic Global Gold Medal (2017) and Silver Medal (2021), Best Paper Awards in IEEE-ROBIO (2019 & 2013), IEEE-RCAR2016, IEEE-CCECE2015, IEEE-Cyber2014 among 30+ others awards.

He frequently served as an expert reviewer/judge for international funding agencies (60+ proposal reviews) of 10+ countries/regions (including Switzerland, Belgium, UK, Kazakhstan, Poland, Hong Kong, Macau, Chilean, China, Singapore etc.) and manuscript peer-reviews 317+ times for journals, including Science Robotics, Nature Biomedical Engineering, Nature Communications among many other top-tier journals (Please refer to the [Web of Science Reviewer Recognition](#) for the service records).



# **Qingpeng Zhang 张清鹏**

**Associate Professor**

**Department of Pharmacology and Pharmacy  
The Musketeers Foundation Institute of Data Science  
The University of Hong Kong**

---

Dr. Zhang Qingpeng is an Associate Professor at the Department of Pharmacology and Pharmacy and the Musketeers Foundation Institute of Data Science, The University of Hong Kong. Dr. Zhang has been dedicated to interdisciplinary research in artificial intelligence and medicine. His research results have been published in top journals such as Nature Human Behaviour, Nature Communications, PNAS, JAMIA, MIS Quarterly, and have been widely reported by media including The Washington Post, The New York Times, The Guardian, Radio-Canada, Ming Pao. He received The President's Award and Outstanding Research Award from CityU, and the Andrew P. Sage Best Transaction Award from IEEE. His collaborative research with the Chinese Academy of Sciences has been recognized as the Outstanding Group in the National Science and Technology System against the COVID-19 Epidemic.



# **Henry Chu 朱嘉行**

**Associate Professor, Department of Mechanical Engineering  
The Hong Kong Polytechnic University**

---

Dr Henry Chu received his Bachelor's degree in Mechanical Engineering (Mechatronics option) from the University of Waterloo, Canada, in 2005, and his MAsc and PhD degrees in Mechanical and Industrial Engineering from the University of Toronto, Canada, in 2007 and 2011, respectively. He was the recipient of the top-ranked Canada Graduate Scholarship (CGS) (2009-2011) and the pre-approved candidate of the Industrial R&D Fellowships (IRDF) program (2012) from the Natural Sciences and Engineering Research Council of Canada (NSERC). Prior to joining the Hong Kong Polytechnic University (PolyU), he was a Postdoctoral Fellow at the City University of Hong Kong through the International Transition Team Scheme (Office of the Provost).

At PolyU, he has secured various multi-disciplinary funds including Early Career Scheme (ECS), General Research Fund (GRF), Environment and Conservation Funds (ECF), Large Equipment Fund for Teaching and collaborative projects from the industries to support his research and teaching. He has supervised/co-supervised students to participate in various competitions/schemes, and received many awards, including Feature Article, Best Conference Paper Finalist, ASM Technology Award, and Jetson Project of the Month.



# INNOVATION GALLERIA | 創新廊

## Public Day: Share & Inspire

Saturday, September 16 | 10:40 AM - 15:00 PM (GMT+8)

### Probiotics

10:40 - 11:30

**Moderator:** Mr. Edmond Lau, HK Business Angel Network

**Panelists:**

Dr. Matey Yordanov, The Matrix Cube  
Dr. Mikhail Bychov, Vim Vitae\*

### STEM Education and Biotechnology

11:30 - 11:45

Prof. Fei Sun, Hong Kong University Science and Technology

11:45 - 12:00

Prof. Jiguang Wang, Hong Kong University Science and Technology

12:00 - 12:15

Dr. Zhaoshi Bao, Capital Medical University

12:00 - 13:00

#### Special Event: Book Fair

#### Featured Authors

- 高福, Gao Fu
- 柳達, Liu Da



13:00 - 14:00

### Lunch Break

# TECHNOLOGY HALL | 科技廳

## Public Day: Share & Inspire

Saturday, September 16 | 10:40 AM - 13:00 PM (GMT+8)

### Get Published in Nature

10:40 - 11:30

**Symposium:** Ms. Mimi Mononen, Nature Journal

### Voice of GBA Scholars

11:30 - 13:00

**Ubiquitin-mediated proteolysis in cancer development and therapy**  
Prof. Hai Rao, Southern University of Science and Technology

**Gut microbes modulate systemic inflammation and behavior disorders in neurologic disease**  
Prof. Wenjing Zhao, Sun Yat-sen University (Shenzhen)

**Bistable insulin response as the stability anchor governing body mass dynamics: weight stability, weight gain, and beyond**  
Dr. Guanyu Wang The Chinese University of Hong Kong (Shenzhen)

\*No biography or information was provided before September 01, 2023.



## **Edmond Lau**

**Director**  
**Hong Kong Business Angel Network**

---

Edmond Lau has 20 years of profound experience in investment, financing and business development. He was the Head of Investment and CFO of Babel Capital focusing on fintech and digital assets investments. He was also the Managing Director of Lingfeng Capital and Head of Innovative Incubation Centre/ Head of Merger & Integration in SFExpress responsible for fintech and logistic tech. Prior to that, he served as the Head of Investment in FIH Mobile and the Investment Director in CLSA Capital Partners focusing on artificial intelligence, mobile Internet, and water technologies. Edmond was previously a Vice President in Citigroup and a senior consultant in Accenture providing financing solutions and strategic advices to telecom, media and technology corporations. Edmond holds an MBA (distinction, Dean's list) from London Business School, a Bachelor of Information Engineering (first class) from Chinese University of Hong Kong, and a Bachelor of Laws from China University of Political Science and Law. Edmond is devoted to technology development and is often invited to be a guest speaker/ panelist at prominent tech functions, such as Hong Kong Fintech Week, Tencent Greater Bay Area Fintech Forum, CFA China Investment Summit, Fintech Forum at The Macao Institute of Financial Services, Singapore Fintech Festival, and Cyberport VC Forum. He is the founding board member of CFA Shenzhen Association, Co-President of Hong Kong Internet Finance Association, board member of Hong Kong Business Angel Network, and a former board member of Hong Kong Society of Financial Analysts. Edmond is a member of Entrepreneurship Committee Advisory Group of Hong Kong Cyberport, ESS Assessment Panel of Innovation and Technology Commission, and teaches tech and investment courses in Universities. Edmond is also a CFA, a FRM, and a Chevening scholar.



## **Matey Yordanov**

**CEO**  
**The Matrix Cube**

---

Matey Yordanov has established and developing multiple businesses in Hong Kong for the past 4 years. His company in the biomedical field, Vim Vitae Limited, develops bioavailability and permeability enhanced endogenous compounds to provide an effective treatment for a range of health conditions. By targeting the most fundamental level of energy production in the human body, the mitochondria, the developed therapeutics are able to protect these cell organelles from stressors and toxins, to enhance energy generation and increase the rate of mitochondrial biogenesis, achieving elevated levels of cellular energy in the body. Furthermore, these therapeutics enable the human organism to autonomously optimize vital biochemical processes in the brain which further augments their efficiency. Extensive human studies are being undertaken and promising preliminary data has been demonstrated.



# ***Jiguang Wang***

**Associate Professor**  
**The Hong Kong University of Science and Technology**

---

Prof. Wang received his Ph.D. in Applied Mathematics from Academy of Mathematics and Systems Science, Chinese Academy of Sciences (CAS), and won the Special Prize of President Scholarship and Excellent PhD thesis Award of CAS. Between 2011 and 2015, he was a Postdoctoral Research Scientist at Columbia University. From 2015, he was named as the Precision Medicine Fellow and promoted to an Associate Research Scientist. He established the Wang Genomics Laboratory @HKUST in 2016, focusing on the application of data science in biology and medicine. He has made substantial contributions to (1) characterization, modelling, and prediction of cancer evolution from genomics (Nat Genet 2016; Nat Genet 2017; Nat Commun 2021); (2) discovery, elucidation, and clinical application of MGMT fusion (Nat Genet 2016; Nat Commun 2020) and METex14 in adult gliomas (Nat Genet 2018; Cell 2018); (3) Discovery of MAP3K3-I441M in CCM (AJHG 2021) and elucidation of EndMT in bAVM (Circ Res 2021); (4) reconstruction of RNA Exosome-regulated non-coding transcriptomes (Nature 2014; Cell 2015). He won the Excellent Young Scientist Award of NSFC (2019), School of Engineering Young Investigator Research Award (2019), School of Science Research Award (2021), and the Zhong Nanshan Youth Science and Technology Innovation Award (2021).



# ***Zhaoshi Bao***

**Postdoctoral Researcher**  
**Jiguang Wang's Lab**

---

ZhaoShi Bao is a Postdoctoral Researcher at Jiguang Wang's Lab. He obtained his Bachelor and Master degrees in Clinical Medicine at the Capital Medical University in 2011. After three-year research at Beijing Tiantan Hospital, Capital Medical University, he earned his M.D. and Ph.D. degrees in Neurosurgery in 2014. He then joined in the Department of Neurosurgery at Beijing Tiantan Hospital in Aug 2014, where he was named as an attending doctor in Dec 2017. Now his major research interest is personalized medicine for patients with glioma.

## 全球領先的**虛擬數據室 (VDR)** 供應商

## The World's Leading **Virtual Data Room (VDR)** Provider

助力生物科技企業**各個研發和融資階段**

Facilitating biotech companies through **all stages of R&D and financing**




### 企業服務 Corporate Services

- 供應鏈管理
- 財務匯報
- 法務協作
- 合約管理
- Supply chain management
- Financial Reporting
- Legal collaboration
- Contract management



### 研發/臨床 R&D/Clinical Trials

- 合作研發
- 臨床端口
- 遠程監控
- 安全共享文件
- Research collaboration
- Clinical portal
- Remote monitoring
- Secured document exchange



### 商業拓展 Business Development

- 授權
- 聯盟管理
- 企業發展
- 融資
- IP licensing
- Alliance Management
- Corporate development
- Financing



了解更多 **Intralinks**

Learn more about **Intralinks**



官方網站 | Website



微信 | WeChat



# Mimmi Mononen

**Associate Editor**  
**Nature Journal**

---

Mimmi joined Nature Communications in September 2022. She received her PhD from Karolinska Institutet, where she studied early human heart development using single-cell RNA sequencing. She continued using single-cell technologies during her postdoc at Shanghai Jiao Tong University, where she worked on cancer stem cells. Mimmi handles manuscripts relating to single-cell biology. She is based in the Shanghai office.



# Hai Rao

**Head, Department of Biochemistry**  
**Southern University of Science and Technology**

---

Dr. Rao earned a Bachelor of Science degree in Chemistry from Wuhan University between 1985 and 1989. They then pursued a Master of Science degree in Chemistry at Boston University from 1989 to 1991. Following this, they obtained a Ph.D. from the State University of New York at Stony Brook & Cold Spring Harbor Laboratory, completing their doctoral studies between 1991 and 1996.

Dr. Rao served as a Postdoctoral Fellow at the California Institute of Technology from 1997 to 2002, under the mentorship of Alex Varshavsky. From 2002 to 2008, they worked as an Assistant Professor in the Department of Molecular Medicine/Institute of Biotechnology at the University of Texas Health, San Antonio. They were then promoted to the position of Associate Professor with tenure, holding this role from 2008 to 2019. From 2019 to October 9, 2020, they served as a Professor with tenure in the Department of Molecular Medicine at the same institution. Since October 12, 2020, they have held the position of Professor with tenure in the Department of Biochemistry at the School of Medicine, the Southern University of Science and Technology.

Dr. Rao's notable accolades include receiving the American Association for Cancer Research Minority-Serving Institution Faculty Scholar Award in Cancer Research in 2006. They were also granted a Postdoctoral Scholarship by the Leukemia & Lymphoma Society of America from 1998 to 2001. In 1996, they were honored with the Graduate Research Award from the State University of New York at Stony Brook.





# Wenjing Zhao

**Professor**

**Sun-Yat-Sen University School of Medicine, China**

---

Dr. Zhao obtained Ph.D. degree from University of Rhode Island, where she focused her studies on the discovery of novel probiotics and the characterization of its mechanisms. After that Dr. Zhao pursued post-doctoral training at the Department of Microbiology and Immunology, Harvard Medical School, by studying the interplays among harmful microbes, commensal microbes, and their host immunity. In 2018, Dr. Zhao joins Sun Yat-sen University and the research of her group is focused on the roles and mechanisms of microbiome in human disease and the development of microbiome-editing technologies. Zhao group's recent research has been published in Nature, Science, PNAS, Protein & Cell, ebiomedicine, and Synthetic and Systems Biotechnology.



# Guanyu Wang

**Associate Professor, School of Medicine**

**The Chinese University of Hong Kong (Shenzhen)**

---

Prof. Guanyu Wang is an associate professor of MED|LHS of the Chinese University of Hong Kong (Shenzhen), a committee member of "The Molecular Systems Biology Specialized Committee" of the Chinese Society of Biochemistry and Molecular Biology, a council member of "The Computational Systems Biology Branch" of Chinese Operations Research Society, and is awarded the title of "Shenzhen Oversea Talents." He was a postdoc and then a research assistant professor of the University of Texas Health Science Center at Houston, a research assistant professor at George Washington University Physics Department, and an associate professor of Southern University of Science and Technology. Prof. Wang published as first or corresponding author more than 50 high-quality papers in journals such as iScience(2), Proc Nat Acad Sci USA, Phys Rev Letts, J Roy Soc Interface (2), IEEE Transactions (2), Trends Immunol, Sci Bull, Theranostics, in total more than 60 papers. He also published a monograph "Analysis of Complex Diseases: A Mathematical Perspective (CRC Press)."

Interdisciplinary research is the defining feature of Guanyu Wang's group, which is targeting fundamental problems in biology and medicine. Professor Wang engages in a research system that centers on biological experiments, with scientific computation, mathematical analysis, and physical thinking as characteristic ingredients.



META Pharmaceuticals Inc.(META for short), **established in August 2021**, is located in the Shenzhen-Hong Kong Science and Technology Cooperation Zone, China. A new R&D center was opened in Hong Kong Science Park(HKSTP) in 2023 and is operating under META Pharmaceuticals (HK) Limited. The name **META** derives from the world metabolism that symbolizes the company's focus on the cross-regulation between metabolism and immunity.

META is the **first pharmaceutical** in the **Asia Pacific** that is developing **first-in-class** drugs based on the groundbreaking theory of **immunometabolism**. This interdisciplinary approach provides **innovative solutions** for autoimmune diseases, cancers, and metabolic disorders. The company currently has **three pipelines**, with the core pipeline planning to initiate **Phase 1 trials in Australia next year**. The team comprises **immunometabolism experts** from Memorial Sloan Kettering Cancer Center, as well as former **chemistry leaders** from Bayer, Sanofi, and Wuxi Apptec. Notably, META Pharmaceutical's compounds have shown **significant improvements in disease progression** in preclinical models of autoimmune diseases like psoriasis, multiple sclerosis and inflammatory bowel disease, **outperforming FDA approved first-line treatments** such as Tofacitinib and Tecfidera.

META has raised \$15M so far and is seeking a total funding round of \$20M to support its IND enabling studies and Phase1 clinical trials. META is actively looking for global development partnership as well.

### Pipeline Development Status

Program	HIT-to-LEAD	LEAD Optimization-to-PCC	IND Enabling	Clinical Phase
1 <sup>st</sup> Gen META-1i	Autoimmune	Psoriasis; Multiple Sclerosis, IBD; SLE .....		
	Metabolic	Rare kidney disease		
1 <sup>st</sup> Gen META-2i	Autoimmune /Metabolic	NAFLD; NASH		
	Metabolic	Hypercholesterolemia; Hyperlipidemia		
1 <sup>st</sup> Gen META-3i	Autoimmune	Rheumatoid arthritis		


# Supporting Organisations

## Organizers



中国科学院微生物研究所  
INSTITUTE OF MICROBIOLOGY  
CHINESE ACADEMY OF SCIENCES

## Co-organizers



## Diamond Sponsors



## Platinum Sponsors



## Gold Sponsors



# Supporting Organisations

## Special Supporting Organisations



## Supporting Organizations / Companies



# Supporting Organisations

## Global Partners

able Pursuing Infinite Opportunities  
Association of Biotechnology Led Enterprises

Bio

Asia Taiwan  
July 26-30, 2023

BIO Africa Convention

BxO ASIA PACIFIC  
Life Sciences, Health, Technology

2024 BIO KOREA  
International Convention  
May 10(Wed) - 12(Fri), 2023 | COEX, SEOUL

BioJapan 2023

BIOTECH NEW ZEALAND

koreaBio

Life Sciences Baltics

sweden BIO  
The Swedish Life Science Industry Organization

Swiss Biotech Association

TCELS  
Thailand Center of Excellence for Life Sciences (Public Organization)

KOREA LIFE SCIENCE WEEK  
Nov. 14 - 16, 2023, COEX, KOREA

## Knowledge Partners

BAIN & COMPANY

Deloitte.

LEK™

## Media Partners

biohaus  
connecting people to science

BIOTECH GATE  
GLOBAL DATABASE  
PRODUCED BY VENTURE VALUATION

CHINESE JOURNAL OF BIOLOGICA

GENE ONLINE

Global Bio & Investment  
環球生技

[iito]

[LSE]

one tv  
亞太第一衛視

PHARMA BOARDROOM

明報

South China Morning Post

WHub  
#StartupPassion

易企说17Talk

eChinaHealth  
世易医健

生物器材网  
www.bio-equip.com

BIOupstream  
上游资源在桔园

## Technology Support Consultant

AIFA  
AIFA TECH LIMITED

SOMA CUBE  
模偶立方影畫

## Office News Distribution Partner

CISION  
PR Newswire

# FOLLOW US ON SOCIAL MEDIA



 *Facebook*



 *LinkedIn*



*WeChat:  
hkbioevents*



 *Instagram*